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Abstract 
A simple, sensitive, rapid and reproducible HPLC Method was developed and validated for 
estimation of Rilpivirine in the presence of degradation products generated from forced decomposition studies. 
The analysis was carried out on Hypersil BDS C18, 250 X 4.6mm, 5μ column using a mixture of ammonium 
acetate Buffer (pH to 6.0 ± 0.05) and Acetonitrile in the proportion 55:45 respectively as a mobile phase at a 
flow rate of 1.2 mL/minute. The wavelength selected for the analysis was 300 nm. The peak for Rilpivirine 
HCl was observed at 10.33 minute.  A linear response was observed in the range of 12.5 - 62.5 μg/mL with a 
correlation coefficient of 0.999. The method was validated for specificity, linearity, precision, accuracy and 
robustness. The obtained results were indicating that the method is selective in analysis of Rilpivirine in the 
presence of degradation products formed under various stress conditions.  
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1. Introduction 
Rilpivirine hydrochloride (REL) is a di-
amino pyrimidine derivative. Chemically, it is 4-[[4-
[[4-[(E)-2-cyanoethenyl]- 2,6-dimethylphenyl] 
amino]-2-pyrimidinyl] amino] benzonitrile 
monohydrochloride (Figure 1).1,4 It is a human 
immunodeficiency virus type 1 (HIV-1) specific, non-
nucleoside reverse transcriptase inhibitor.[3-6]  It is a 
white to almost white powder. . It is practically 
insoluble in water over a wide pH range. It is soluble 
in N,N-dimethylformamide (DMF) and N,N-
dimethylacetamide, slightly soluble in methanol, 
propylene glycol and 1-methoxy-2-propanol. The 
active substance does not have chiral centres and is 
not considered hygroscopic.6-9 Rilpivirine was 
approved by the European Medicines Agency, UK 
and Therapeutic Goods Administration, (TGA) 
Australia.7-8 Rilpivirine HCl Tablets are available for 
oral administration in strength of 130 mg of 
Rilpivirine HCl (equivalent to approximately 25mg of 
Rilpivirine).  
Earlier publications have described high-
performance liquid chromatography (HPLC) methods 
useful for the quantification of REL in pharmaceutical 
dosage forms.9-11 However; these methods involve 
arduous sample preparation and long 
chromatographic run times. 
It was felt necessary to develop a simple, precise, and 
rapid HPLC method for the quantitative 
determination of REL.12 The current research work 
deals with the development of HPLC method and its 
validation as per International Conference on 
Harmonisation (ICH) guidelines13. The developed 
method was found to be selective, accurate, precise, 
reliable, and economical.  
 
Figure 1: Structure of Rilpivirine HCl 
 
4-[[4-[[4-[(E)-2-cyanoethenyl]-2,6-
dimethylphenyl]amino]-2-
pyrimidinyl]amino]benzonitrile monohydrochloride 
 
2. Materials and Methods 
2.1. Chemicals and reagents 
Rilpivirine HCl working standard was 
procured from Matrix laboratories pvt. Ltd., 
Hyderabad (India). Acetonitrile and water used were 
of HPLC grade (Qualigens, Mumbai). Analytical 
reagent grade Ammonium Acetate, Triethylamine, 
Acetic Acid was used. 
2.2. Equipments  
HPLC system:  Waters - Alliance 510 with UV- 484 
Data Ace software 
Column:  Hypersil BDS C18, 250 X 4.6mm, 5μ  
Balance – Mettler Toledo 205  
Ultrasonicator, ENERTECH Electronics Pvt. Ltd. 
 
2.3. Preparation of solutions  
2.3.1. Diluent 
A mixture of ammonium acetate buffer (pH 
6.0 ± 0.05) and Acetonitrile in the proportion 20:80 
respectively, filtered through 0.5 μ Nylon membrane 
filter was used as diluent. 
2.3.2. Rilpivirine HCl Standard solution 
An accurately weighed 50 mg of Rilpivirine 
HCl working standard was transferred to a 100 mL 
volumetric flask and dissolved in diluent by 
sonication. The solution was diluted to mark with the 
diluent to give the stock solution of concentration 500 
µg/mL. Aliquot of 5.0 mL from the stock solution 
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was diluted to 100 mL with the diluent to give the 
working standard solution of concentration 25 µg/mL. 
The solution was then filtered through 0.45 μ nylon 
filter. 
2.3.3. Preparation of Test Solution 
Twenty tablets were accurately weighed, 
their average weight was determined and they were 
finely powdered. The powder equivalent to 50 mg of 
Rilpivirine HCl was transferred to a 100 mL 
volumetric flask. About 70 mL of diluent was added 
and sonicated for 10 minutes. The solution was 
diluted to volume with Diluent. The aliquot of 5.0 mL 
from this solution was transferred into a 100 mL of 
volumetric flask and diluted to volume with the 
diluent. The solution was filtered through 0.45μ nylon 
filter. 
2.4. Chromatographic Conditions 
Analysis was carried out on Hypersil BDS C18, 250 
X 4.6 mm, 5μ column using a mixture of ammonium 
acetate Buffer (pH to 6.0 ± 0.05) and Acetonitrile in 
the proportion 55:45 respectively as a mobile phase at 
a flow rate of 1.2 mL/minute. The column 
temperature was set at 30 °C. The detection was 
carried out at 300 nm using a PDA detector. 
2.5. Calibration Curve 
 From the standard stock solution of 
Rilpivirine HCl aliquots were transferred to series of 
100 mL volumetric flasks and volume was made up to 
the mark with diluents to give solutions of 
concentrations in the range of 12.5 - 62.5 μg/mL. The 
chromatograms and peak areas of these solutions 
were measured at 300 nm and a calibration curve was 
constructed, by plotting the area against the 
corresponding drug concentration.  
2.6. Forced Degradation 
The forced degradation studies were performed to 
establish the stability indicating nature and specificity 
of the assay method and to observe any degraded 
compounds. Rilpivirine HCl working standard and 
Sample (Rilpivirine HCl Tablets 50 mg) were 
subjected to stress with 5N HCl, 5N NaOH, 3% H2O2 
and Thermal degradation at 60°C in presence of 80 
%RH (Table 1). Chromatograms were recorded for 
all the above solutions.  
Table 1:  Forced Degradation Conditions 
Stress condition Description of stress 
condition 
Acid degradation 5N HCl heated at about 
60 °C for 10 min on water 
bath. 
Alkali degradation 5N NaOH heated at about 
60 °C for 10 min on a 
water bath. 
Oxidation degradation 3%v/v H2O2 heated at 
about 60 °C for 10 min on 
a water bath. 
Thermal degradation 
in presence of 
humidity 
60°C @ 80 %RH for 7 
days 
 
2.7. Validation of the Method 
2.7.1. Linearity  
For the linearity study standard solutions of 
Rilpivirine HCl were prepared in the range starting 
from 50 % to 250 % of the theoretical concentration 
of assay preparation (12.5 - 62.5 μg/mL). The 
linearity graph of concentration against peak response 
was plotted and the correlation coefficient was 
determined. 
2.7.2. Specificity   
 The analyte should have no interference 
from other extraneous components and be well 
resolved from them. To determine the specificity of 
the method, the mixture of reference standard 
Rilpivirine HCl and the degradation products was 
injected and chromatogram was recorded. The sample 
solution was then injected and the chromatogram was 
obtained. The sample chromatogram was compared 
with the standard chromatogram.  
Figure 2: Typical chromatogram of Standard Rilpivirine HCl 
 
2.7.3. Precision 
 Precision of the method was studied in terms 
of method precision and intermediate precision. 
Method Precision 
Six test solutions of Rilpivirine HCl tablets were 
prepared as per the analytical method. The % RSD of 
assay of six test solutions was calculated. 
 
Intermediate precision 
Six test solutions of Rilpivirine HCl Tablets were 
prepared as per the analytical method on different 
day. These test solutions were analyzed by a different 
analyst. The % RSD of assay results of twelve test 
solutions (six samples from method precision and six 
samples from intermediate precision) was calculated.   
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2.7.4. Accuracy (Recovery) 
Accuracy study was performed by analyzing 
Rilpivirine HCl test solutions spiked with a quantity 
of Rilpivirine HCl standard to produce three different 
concentration solutions equivalent to 80 %, 100 % 
and 120 % of test concentration. 
2.7.5. Robustness  
To determine the robustness of the method 
the experimental conditions were deliberately altered 
and peak area was evaluated. Three test solutions of 
the same lot of Rilpivirine HCl from tablets were 
prepared as per analytical method.  These solutions 
were injected with different chromatographic 
conditions as Change in flow rate (± 0.2 mL/minute), 
Change in Column Oven Temp 300C (±50C), Change 
in wavelength (± 2 nm) and Change in pH of mobile 
phase (± 0.2). When the effect of altering one set of 
conditions was tested, the other conditions were held 
constant at the optimum values. 
2.7.6. Limit of Detection and Quantitation 
Limit of Detection and Quantitation is 
established by injecting six times very low 
concentration of Rilpivirine HCl standard preparation 
i.e. 1.0ppm and 2.0ppm.  
2.8 Assay of Rilpivirine HCl in tablets 
Six replicate injections of test solution were 
injected and chromatogram and peak area were 
recorded. The concentration of tablet solution was 
determined using linear regression equation of 
calibration graph and amount of drug in tablet was 
determined. 
2.9. System Suitability Parameters 
Five replicate injections of system suitability 
solution (Rilpivirine HCl standard working solution) 
were injected. The retention time, areas, theoretical 
plates, peak asymmetry and resolution were 
calculated for standard solutions 
 
3. Result and Discussion 
A new HPLC method was developed and 
validated for estimation of Rilpivirine HCl in the 
presence of degradation products using a mixture of 
ammonium acetate Buffer (pH to 6.0 ± 0.05) and 
Acetonitrile in the proportion 55:45 respectively as a 
mobile phase. The average retention time for 
Rilpivirine HCl was found to be 10.33 minute. The 
details of findings are as below. 
3.1. Forced Degradation 
 The number of degradation peaks observed 
in different stress condition was as follows: 
Acid Degradation 
One degradation peak was observed in acid 
degradation of standard preparation (Figure 3) as 
well as sample preparation. 
Alkali Degradation 
One degradation peak was observed in alkali 
degradation of standard preparation (Figure 4) and 
two degradation peaks were observed in alkali 
degradation of sample preparation. 
Peroxide Degradation 
Three degradation peaks were observed in 
peroxide degradation of standard preparation (Figure 
5) and five degradation peaks were observed in 
peroxide degradation of sample preparation. 
Thermal With Humidity Degradation (60°C & 
80%RH) 
Four degradation peaks were observed in 
thermal with humidity degradation of standard 
Preparation (Figure 6) and three degradation peaks 
were observed in thermal with humidity degradation 
of sample. 
The percent degradation of Rilpivirine HCl found is 
shown in Table 2 
Table 2:  Percent Degradation of Rilpivirine HCl 
   
% Degradation 
Acid 
Degradation 
Alkali 
Degradation 
Peroxide 
Degradation 
Thermal With Humidity 
Degradation 
API 0.048 0.002 0.029 0.085 
Tablet 0.002 0.099 0.008 0.296 
 
Figure 3: Acid degradation of standard Rilpivirine HCl 
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Figure 4: Alkali degaradation of standard Rilpivirine HCl 
 
Figure 5: Peroxide degradation of standard Rilpivirine HCl 
 
Figure 6: Thermal with Humidity degradation of standard Rilpivirine HCl 
 
3.2. Linearity  
The average peak area of Rilpivirine HCl 
peak at each concentration level was determined and 
the linearity graph was plotted over the range of 12.5 
- 62.5 μg/mL. The results of linearity study are as 
given in Table 3. The linearity plot of peak area of 
Rilpivirine HCl Vs. standard concentration is shown 
in Figure 7. 
 
Table 3: Linearity Data for Rilpivirine HCl 
Linearity range (µg/mL) 12.5 – 62.5 
Slope 221.5 
Y-intercept -805 
Correlation coefficient (r2) 0.999 
 
Figure 7: Linearity plot of standard Rilpivirine HCl 
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3.3. Specificity 
The peaks due to degradation products were 
found to be well separated from the peak due to 
Rilpivirine HCl. The peak purity criteria of 
Rilpivirine HCl were found to pass at each condition 
of degradation. 
3.4. Precision 
Precision of the method was studied in terms 
of method precision and intermediate precision. 
Precision was expressed in terms of % R.S.D. All 
values for precision were within recommended limits. 
Method precision 
Analysis of six separate solutions of 
Rilpivirine HCl showed the repeatability of the 
method. The results of assay obtained from six test 
solutions preparations are given in Table 4. 
Table 4: Results of Method Precision 
% Assay of Rilpivirine HCl 
 (Mean ± SD)* 
101.22  ± 1.33 
(%) Relative Standard 
Deviation  
1.31 
*-Mean of six determinations 
Intermediate precision 
The % RSD of assay results of analysis 
carried out on two different days as summarized in 
Table 5 indicated that the method is precise and 
reproducible. 
Table 5: Results of Intermediate Precision 
% Assay of Rilpivirine HCl 
(Mean ± SD)* 
100.54 ± 1.33 
(%) Relative Standard 
Deviation (n=12) 
1.33 
*-Mean of twelve determinations 
3.5. Accuracy (Recovery) 
The results of recovery studies showed the 
accuracy of the method. The recoveries were ranged 
between 99.76 – 101.44 %, Results obtained are given 
in Table 6.  
Table 6: Results of Recovery Studies 
Level 
Amount 
added  
(µg/mL) 
Amount 
found  
(µg/mL) 
%Recovery* 
(Mean ± SD) 
80% 20 20.08 100.38 ± 1.04 
100% 25 25.36 101.44 ± 1.85 
120% 30 29.93 99.76 ± 1.35 
Mean ± SD 100.53 ± 0.85 
% RSD 0.85 
*-Mean of three determinations 
3.6. Robustness  
The robustness of a method is its capacity to 
remain unaffected by small changes in conditions. 
Robustness of the method was indicated by the small 
% RSD observed for the assay of Rilpivirine HCl 
sample at deliberately altered experimental 
conditions. The optimum mobile phase flow rate was 
1.2 mL min-1. This was changed by 0.2 units to 1.0 
and 1.4 mL min-1 and the effect was studied. 
Similarly, the effect of change in column temperature 
was studied at 25 and 35°C. The effect of change in 
wavelength was studied at 298nm and 302 nm. The 
effect of change in pH of mobile phase was studied at 
pH 5.8 and pH 6.2. For all changes of conditions the 
sample was assayed in triplicate. 
Assay of Rilpivirine HCl for all deliberate 
changes of conditions was within 99.80– 101.02%. 
The complete results are shown in Table 7. 
Table 7: Results of Robustness Studies 
Condition % Assay* %RSD  
Flow rate (optimum flow rate ± 0.2 mL/min) 
1.0 mL/min 99.91 0.25 
1.4 mL/min 100.11 1.81 
Column temperature (optimum temperature ± 5°C) 
25°C 100.77 0.1 
35°C 101.02 0.95 
Wavelength (optimum  Wavelength  ± 2 nm) 
298 nm 100.64 0.13 
302 nm 100.85 0.22 
pH (optimum  pH  ± 0.2) 
pH 5.8 100.40 1.06 
pH 6.2 99.80 0.47 
*-Mean of three determinations 
3.6. Limit of Detection and Quantitation 
Limit of Detection and Quantitation was 
observed to be 1.0ppm and 2.0ppm respectively 
3.7. Assay of Rilpivirine HCl in tablets.  
 The concentration of tablet solution was 
determined using linear regression equation (using 
slope and Y-intercept) and amount of drug in tablet 
was determined. The results of assay in tablets are 
summarized in Table 8. 
Table 8: Results of Assay of Rilpivirine HCl in 
tablets 
Labeled claim (mg) 25 
Amount found  (mg) mean  
SD* 
24.96  0.20 
% labeled claim  99.85 
% RSD 0.79 
*-Mean of six determinations 
3.8. System Suitability Parameters  
System suitability parameters were tested for 
the chromatographic conditions and results are as 
shown in Table 9. 
Table 9: System Suitability Parameters 
Parameter Average  %RSD 
Retention time 10.33 minute 0.1 
Peak Area 4678.42 0.90 
HETP 5482  
Tailing Factor 1.31  
 
4. Conclusion 
 A simple, rapid and reliable HPLC method 
has been developed and successfully validated for 
estimation of Rilpivirine HCl in the presence of 
degradation products. The results of the validation 
tests indicated that the method was accurate, precise, 
robust, and stability indicating. This method is 
suitable for the routine quality control of the tablet 
dosage form.   
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